🚀 VC round data is live in beta, check it out!
CareDx Valuation Multiples
Discover revenue and EBITDA valuation multiples for CareDx and similar public comparables like Novogene, Mirxes Holding, Eckert & Ziegler, OPKO Health and more.
CareDx Overview
About CareDx
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Founded
1998
HQ
Employees
765
Website
Financials (LTM)
EV
$798M
CareDx Financials
CareDx reported last 12-month revenue of $394M and EBITDA of $34M.
In the same LTM period, CareDx generated $269M in gross profit, $34M in EBITDA, and had net loss of ($17M).
Revenue (LTM)
CareDx P&L
In the most recent fiscal year, CareDx reported revenue of $380M and EBITDA of $32M.
CareDx expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $394M | XXX | $380M | XXX | XXX | XXX |
| Gross Profit | $269M | XXX | $257M | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | $34M | XXX | $32M | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | 8% | XXX | XXX | XXX |
| EBIT Margin | (7%) | XXX | (7%) | XXX | XXX | XXX |
| Net Profit | ($17M) | XXX | ($21M) | XXX | XXX | XXX |
| Net Margin | (4%) | XXX | (6%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
CareDx Stock Performance
CareDx has current market cap of $964M, and enterprise value of $798M.
Market Cap Evolution
CareDx's stock price is $18.75.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $798M | $964M | 0.0% | XXX | XXX | XXX | $-0.42 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCareDx Valuation Multiples
CareDx trades at 2.0x EV/Revenue multiple, and 23.8x EV/EBITDA.
EV / Revenue (LTM)
CareDx Financial Valuation Multiples
As of April 8, 2026, CareDx has market cap of $964M and EV of $798M.
Equity research analysts estimate CareDx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CareDx has a P/E ratio of (58.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $964M | XXX | $964M | XXX | XXX | XXX |
| EV (current) | $798M | XXX | $798M | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | 23.8x | XXX | 25.2x | XXX | XXX | XXX |
| EV/EBIT | (31.1x) | XXX | (31.8x) | XXX | XXX | XXX |
| EV/Gross Profit | 3.0x | XXX | 3.1x | XXX | XXX | XXX |
| P/E | (58.2x) | XXX | (45.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 22.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified CareDx Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
CareDx Margins & Growth Rates
CareDx's revenue in the last 12 month grew by 13%.
CareDx's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.4M for the same period.
CareDx's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CareDx's rule of X is 43% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
CareDx Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Growth | 32% | XXX | 21% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 23% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 43% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 26% | XXX | 27% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 27% | XXX | 28% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 18% | XXX | 19% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 74% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
CareDx Public Comps
See public comps and valuation multiples for other Diagnostics & Genomics and Health Data & Analytics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Novogene | XXX | XXX | XXX | XXX | XXX | XXX |
| Mirxes Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Eckert & Ziegler | XXX | XXX | XXX | XXX | XXX | XXX |
| OPKO Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Clover Health | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CareDx M&A Activity
CareDx acquired XXX companies to date.
Last acquisition by CareDx was on XXXXXXXX, XXXXX. CareDx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by CareDx
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCareDx Investment Activity
CareDx invested in XXX companies to date.
CareDx made its latest investment on XXXXXXXX, XXXXX. CareDx invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by CareDx
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout CareDx
| When was CareDx founded? | CareDx was founded in 1998. |
| Where is CareDx headquartered? | CareDx is headquartered in United States. |
| How many employees does CareDx have? | As of today, CareDx has over 765 employees. |
| Who is the CEO of CareDx? | CareDx's CEO is John Walter Hanna. |
| Is CareDx publicly listed? | Yes, CareDx is a public company listed on Nasdaq. |
| What is the stock symbol of CareDx? | CareDx trades under CDNA ticker. |
| When did CareDx go public? | CareDx went public in 2014. |
| Who are competitors of CareDx? | CareDx main competitors are Novogene, Mirxes Holding, Eckert & Ziegler, OPKO Health. |
| What is the current market cap of CareDx? | CareDx's current market cap is $964M. |
| What is the current revenue of CareDx? | CareDx's last 12 months revenue is $394M. |
| What is the current revenue growth of CareDx? | CareDx revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of CareDx? | Current revenue multiple of CareDx is 2.0x. |
| Is CareDx profitable? | Yes, CareDx is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of CareDx? | CareDx's last 12 months EBITDA is $34M. |
| What is CareDx's EBITDA margin? | CareDx's last 12 months EBITDA margin is 9%. |
| What is the current EV/EBITDA multiple of CareDx? | Current EBITDA multiple of CareDx is 23.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.